课题组长：黄玉辉
课题组长期从事肿瘤免疫学研究，致力于探索肿瘤免疫微环境的形成机制及其在肿瘤免疫治疗中的应用，在肿瘤微环境与免疫细胞的交互作用机制、肿瘤免疫耐受机理与干预策略等方面开展了一系列创新性的研究工作。在国际上首次提出了Immunevascular crosstalk（免疫血管交互作用）的概念和率先证明了免疫检查点抑制剂治疗可以通过重塑肿瘤血管来发挥作用的新机制。这些研究成果为肿瘤免疫治疗药效评估、疗效预测和联合用药提供了一个全新的思路，将促进新型肿瘤免疫治疗药物的研发和临床治疗效果的提升。相关成果已经发表在Nat Rev Immunol、J Clin Invest、Cancer Cell、PNAS 等本领域国际一流期刊上。课题组成员主持国家自然科学基金面上项目2 项，作为子课题负责人参与国家重点研发项目1 项，入选江苏省“特聘教授”、江苏省“双创团队”、江苏省“六大人才高峰”、苏州工业园区第九届“科技领军人才”等。
代表性成果 Representative Achievements：
论文
1. Huang Y*, Kim BYS, Chan CK, Hahn SM, Weissman IL, Jiang W *. Improving immune-vascular crosstalk for cancer immunotherapy. Nat Rev Immunol 2018; 18:195-203.
2. Zheng X#, Fang Z#, Liu X, Zhou P, Deng S, Wang X, Zhang C, Yin R, Hu H,Chen X, Zhao Y, Lin SH, Qin S, Wang X, Kim BYS, Zhou P, Jiang W, Wu Q, Huang Y*. Increased vessel perfusion predicts the efficacy of immune checkpoint
1. blockade. J Clin Invest 2018; 128: 2104-15.
2. Deng S#, Zhang G#, Kuai J, Fan P, Wang X, Zhou P, Yang D, Zheng X, Liu X, Wu Q*, Huang Y*. Lentinan inhibits tumor angiogenesis via interferon γ and in a T cell independent manner. J Exp Clin Cance. Res 2018.
3. Peterson TE#, Kirkpatrick ND#, Huang Y#, Farrar CT, Marijt KA, Kloepper J, Datta M, Amoozgar Z, Seano G, Jung K, Kamoun WS, Vardam T, Snuderl M, Goveia J, Chatterjee S, Batista A, Muzikansky A, Leow CC, Xu L, Batchelor TT, Duda DG, Fukumura D, Jain RK*. Dual inhibition of Ang-2 and VEGF receptors normalizes tumor vasculature and prolongs survival in glioblastoma by altering macrophages. Proc Natl Acad Sci U S A 2016; 113: 4470-5.
4. Jiang W#, Huang Y#, An Y, Kim B*. Remodelling Tumor vasculature to enhance delivery of intermediate-sized nanoparticles. ACS Nano 2015;9: 8689-96. Huang Y, Goel S, Duda DG, Fukumura D, Jain RK*. Vascular normalization as an emerging strategy to enhance cancer immunotherapy. Cancer Res 2013; 73:2943-8.
5. Huang Y, Yuan J, Righi E, Kamoun WS, Ancukiewicz M, Nezivar J, Santosuosso M, Martin JD, Martin MR, Vianello F, Leblanc P, Munn LL, Huang P, Duda DG, Fukumura D, Jain RK*, Poznansky MC. Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy. Proc Natl Acad Sci U S A 2012, 109: 17561-6.
6. Huang Y, Snuderl M, Jain RK*. Polarization of tumor-associated macrophages: a novel strategy for vascular normalization and antitumor immunity. Cancer Cell 2011, 19: 1-2.